All In Biotech

Drug Trial Radar · NCT06128551

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

534

Planned (sponsor's estimate)

Start

Nov 14, 2023

Primary completion

Dec 2028

Study completion Jun 2029

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
First posted
Nov 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Conditions

  • Non-Small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer
  • Pancreatic Ductal Adenocarcinoma

Interventions

  • ElironrasibDrug

    oral tablets

  • DaraxonrasibDrug

    oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with adverse events (AEs) in Phase 1bTime frame: Up to approximately 3 years
  2. Changes in vital signs in Phase 1bTime frame: Up to approximately 3 years
  3. Changes in clinical laboratory test values in Phase 1bTime frame: Up to approximately 3 years
  4. Dose Limiting Toxicities in Phase 1bTime frame: 21 days
  5. Changes in ECGs in Phase 1bTime frame: Up to approximately 3 years
  6. Overall Response Rate (ORR) in Phase 2Time frame: Up to approximately 3 years

Locations

56 sites in 7 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Withdrawn

  • UC IRVINE Health

    Orange, California · Recruiting

  • UC Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Stanford Cancer Institute

    Stanford, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Moffitt Cancer Center and Research Institute

    Tampa, Florida · Recruiting

  • Community Health Network

    Indianapolis, Indiana · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Cancer

    Detroit, Michigan · Withdrawn

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of Oklahoma

    Oklahoma City, Oklahoma · Recruiting

  • Allegheny Health Network

    Pittsburgh, Pennsylvania · Recruiting

  • Sarah Cannon Research Institue

    Nashville, Tennessee · Recruiting

  • Mary Crowley Cancer Research

    Dallas, Texas · Completed

  • MD Anderson

    Houston, Texas · Recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • NEXT Oncology San Antonio

    San Antonio, Texas · Recruiting

  • START Texas

    San Antonio, Texas · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

  • West Cancer Institute

    Angers, France · Recruiting

  • Institut Bergonie

    Bordeaux, France · Recruiting

  • Hospital Louise Pradel

    Bron, France · Recruiting

  • Oscar Lambret Center of Lillle

    Lille, France · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Cancer Institute of Montpellier

    Montpellier, France · Recruiting

  • CHU Nantes

    Nantes, France · Recruiting

  • Institute of Cancer of Strasbourg

    Strasbourg, France · Withdrawn

  • Universitäts Klinikum Köln

    Cologne, Germany · Recruiting

  • Klinikum Esslingen GmbH

    Esslingen am Neckar, Germany · Recruiting

  • Krankenhaus Bethanien Moers

    Moers, Germany · Recruiting

  • Klinkum Nurnberg Paracelsus Medical Unviersity

    Nuremberg, Germany · Recruiting

  • Department of Medical Oncology - Azienda Ospedaliero Uniersitaria delle Marche

    Ancona, Italy · Recruiting

  • Centro Di Riferimento Oncologico

    Aviano, Italy · Recruiting

  • Institute Romagnolo per lo Studio Tumori

    Meldola, Italy · Recruiting

  • Niguarda Cancer Center

    Milan, Italy · Recruiting

  • Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"

    Naples, Italy · Recruiting

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.